Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Asthma/Steroid Withdrawal Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00395239
Recruitment Status : Terminated (This project will resume upon the completion of other research committments.)
First Posted : November 2, 2006
Last Update Posted : May 26, 2016
Information provided by (Responsible Party):
Irvin Mayers, University of Alberta

Brief Summary:

The investigators propose to study the patterns of metabolite changes in subjects with asthma to determine if there is a predictable pattern prior to, and post, clinical exacerbation.

Hypothesis: 1. Metabolite profiles will change prior to detection of a clinical exacerbation in subjects with asthma.

2. There will be a measurable temporal delay before metabolite profiles return to baseline following anti-inflammatory therapy of an exacerbation of asthma.

Condition or disease Intervention/treatment Phase
Asthma Drug: inhaled corticosteroid Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Temporal Sequence of Inflammatory Mediators During a Controlled Exacerbation of Asthma by Steroid Withdrawal.
Study Start Date : October 2006
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: 1 Drug: inhaled corticosteroid
Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
Other Name: Flovent; Pulmicort; Alvesco.

Primary Outcome Measures :
  1. Metabolite changes in induced sputum [ Time Frame: 20 weeks ]
  2. Metabolite changes in urine [ Time Frame: 20 weeks ]

Secondary Outcome Measures :
  1. Health related quality of life status [ Time Frame: 20 weeks ]
  2. Peak expiratory flow measurements [ Time Frame: 20 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Non-smoker (less than 1 pack-year).
  2. Age greater than 18 years old.
  3. Ability to obtain informed consent.
  4. Pulmonary Function Tests demonstrating greater than 12% FEV1 reversibility following beta agonist OR a methacholine challenge consistent with airways hyper-reactivity.
  5. Evidence of atopy on standardized skin test battery.
  6. Mild to moderate persistent asthma classification by GINA guidelines.
  7. No severe exacerbations in the preceding 3 months (defined as emergency room visit, course of oral prednisone or hospitalization).
  8. Access to internet.

Exclusion Criteria:

  1. Unstable asthma.
  2. Patient not on inhaled corticosteroids.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00395239

Layout table for location information
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Sponsors and Collaborators
University of Alberta
Layout table for investigator information
Principal Investigator: Irvin Mayers, MD, FRCPC University of Alberta

Layout table for additonal information
Responsible Party: Irvin Mayers, Dr. Irvin Mayers, University of Alberta Identifier: NCT00395239    
Other Study ID Numbers: Asthma/Steroid Withdrawal
First Posted: November 2, 2006    Key Record Dates
Last Update Posted: May 26, 2016
Last Verified: August 2010
Keywords provided by Irvin Mayers, University of Alberta:
Inhaled corticosteroid
Induced sputum
Virtual Asthma Clinic
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases